sana biotechnology ipo

S even months after reeling in $700 million in a venture round, Sana Biotechnology makes a debut in Wall Street with a $587.5 million IPO. It was the second-highest valuation among all private biotechs, according to Silicon Valley Bank's annual industry report. Their stock opened with $25.00 in its Feb 4, 2021 IPO. Sana Biotechnology, a Seattle gene regulation startup led by several co-founders of Juno Therapeutics, raised $588 million in its IPO. Sana Biotechnology raised $700 million in initial financing in June 2020 through venture capital. UPDATE 1:20 p.m.: Shares of Sana gained more than $10 from its initial offering price, up 40% in its debut and closing at $35.10. Sana Biotechnology Stock. ... Sana needs the IPO cash because of its high burn rate. Interested in learning more? “Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines,” the company wrote in its IPO prospectus. While earlier pre-IPO investing was limited to hedge funds, vat equity firms, and accredited investors, the SharesPost and EquityZen platforms allow individual investors to buy pre-IPO shares. Seattle-based Sana Biotechnology has filed to go public on the Nasdaq. Sana Biotechnology – the company that develops cell engineering techniques to treat a variety of cancers has filed to raise $323 million in its IPO. At the GeekWire Summit last October, Sana CEO Steve Harr explained how they are essentially turning the body into its own “bioreactor,” which can fend off disease. Sana Biotechnology shares are still privately held. The company mentioned in the prospectus, “Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines.”. In 2020, Sana Biotechnology licensed technology from Harvard University to help with its efforts to develop off-the-shelf cell therapies. Sana Biotechnology filed to go public on Jan. 13. Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, raised $588 million by offering 23. The company hasn't set the pricing terms of the IPO yet. Industry: Pharmaceuticals ET by Tomi Kilgore Sana Biotechnology started at neutral with $35 stock price target at J.P. Morgan That exceeded the price target range set earlier in the week when the company said it was looking to price at $23 to 24 per share. You can listen to a snippet of Harr’s talk from the GeekWire Summit here: Madrona Venture Group partners with Founders from Day One for the Long Run. Morgan Stanley, Goldman Sachs, JPMorgan Chase, and Bank of America are leading the offering. Company Name: Sana Biotechnology Stock Symbol: SANA Exchange: NASDAQ Status: Priced IPO Date: 2/4/2021 IPO Price: 35.00 ( … Subscribe to GeekWire's free newsletters to catch every headline, presented by First Tech Federal Credit Union, Ciara joins board of Seattle startup Amperity to help guide corporate social responsibility efforts, Google’s AI-focused venture fund leads $5.4M investment for Seattle analytics startup Iteratively, RBC Signals raises $1.2M to get ready for the coming boom in satellite data traffic, Avalara acquires assets from DAVO, which helps small businesses automate sales tax compliance, Swiss battery venture teams up with MagniX and Harbour Air on electric plane, Inside the booming market for buying Amazon sellers: Secrets and insights from an acquirer, Amazon criticizes European soccer ‘Super League’ as anticompetitive, says Prime Video not involved, Vicis high-tech helmets take top 3 spots in NFL’s annual performance ranking of equipment, Report: Discord ends acquisition talks with Microsoft, Put your head in the cloud: Microsoft unveils immersive digital tour for deep dive on data centers, Amazon opening first hair salon in London in bid to test new technology and sell more beauty products, How the Pacific Northwest is playing a key role in the burgeoning world of carbon capture tech, Mental Health Match helps people find the right therapist, and finds a new home in Portland, Amazon cancels ‘Lord of the Rings’ MMO in latest hiccup for company’s gaming ambitions, Seattle startup adyn raises $2.5M from 23andMe CEO and others for birth control prescription test. The company plans to trade on Nasdaq under the ticker symbol "SANA." Investors can talk to their stockbroker or an investment firm that focuses on pre-IPO shares or fundraisings. Sana Biotechnology is still a preclinical company without a single drug in a clinical trial. Sana is still at a preclinical stage but wants to value the company at a price nearly $4.5 billion. Obviously, Wall Street liked what they saw in Sana, a money-losing company that has yet to drive any revenue. The venture capital included investors like Arch Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, and Baillie Gifford. The biotech startup wants to raise $150 million after securing more than $700 million in its initial funding round in 2020. EquityZen is a marketplace for shares of proven pre IPO tech companies. We’ll celebrate the Pacific Northwest’s leading innovators, entrepreneurs and technologists at one of the most anticipated tech events: The GeekWire Awards, presented by Wave Business. Sana boosted the number of shares it plans to sell in an initial public offering this week, and now expects to sell 22 million shares at $23 to $24 per share. If those perceptions take root, Sana notes that some government agencies may restrict treatments that utilize gene editing, or medical professionals may not prescribe it. Learn more about underwritten and sponsored content on GeekWire. The proceeds will fund the development of the company’s in vivo and ex vivo cell engineering technology and push the pipeline drugs through preclinical work. Seattle-based Sana Biotechnology filed paperwork on January 14 for an initial public offering. Sana’s gene editing tech could provide treatments for a number of diseases. People may receive compensation for some links to products and services on this website. At pricing, Sana Biotechnology commands a fully diluted market value of $4.9 billion, making it the largest preclinical biotech IPO ever. Now what? AACQ SPAC Stock Falls to Near All-Time Low—Will It Recover. Try one of our most popular episodes with Hope Cochran, entrepreneur, CFO, and now board member and investor at Madrona. Listen here or on Apple, Spotify, Google, Amazon, or Stitcher. Sana Biotechnology IPO Info. Offers may be subject to change without notice. Let us know. The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share. Sana Biotechnology, Inc. (1770121) SEC Filing S-1 IPO report for the period ending Wednesday, January 13, 2021 The company priced 23.5 million shares at $25, for a fully diluted market value of around $4.9 billion. Sana Biotechnology is working on a string of drug candidates utilising stem cell technology and has raised a huge $700m for its first funding round. Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology (SANA) intends to raise as much as $345 million in an IPO of its common stock at about $4B valuation, at a price range of $20 to $23. Sana Biotechnology is funded by 12 investors. Sana Biotechnology designs cells to treat cancer, central nervous system diseases, heart disease, and genetic disorders. Sana Biotechnology, an unusually heavily financed cell and gene therapy developer run by former Juno Therapeutics executives, has raised $588 million in an initial public offering, a strong sign that interest in emerging biotechs hasn't waned after a record-setting 2020.. There is a true IPO bonanza going on at the moment and we’ll get to that in a moment, but there’s still a good deal of money sloshing around the sector for early-stage deals too. So, how can you buy pre-IPO stock? - Renaissance Capital IPO Investing The company, led by former executives of Juno Therapeutics, priced 23.5 million shares at $25 per share on Wednesday evening. - Renaissance Capital It has raised a total of $700M from 12 institutional investors including Bezos Expeditions, Google Ventures, Baillie Gifford, Canada Pension Plan Investment Board and others. Seattle-based Sana Biotechnology is shooting to raise $150 million in its initial public offering, but soon after is expected to see its market value … However, gene editing is not accepted by some, a risk factor that Sana points out in its IPO filing. (Note: Sana Biotechnology upsized its IPO to 22 million shares at $23 to $24 – up from its initial terms of 15 million shares at $20 to $23 – in an S-1/A filing dated Feb. 3, 2021.) It typically takes more than eight years to reach that milestone. Genworth Mortgage Holdings Files IPO to Go Public. Sana Biotechnology (NASDAQ:SANA), one of the most ambitious biotech startups in the world, raised $588 million in an initial public offering (IPO). All Rights Reserved. Subscribe to GeekWire's free newsletters to catch every headline. They can give you suggestions and guidance on how to invest in companies before they go public. Sana Biotechnology raised $587.5 million in an initial public offering, a significant cash haul that the 3-year-old Seattle company will use to continue a quest to treat disease using cutting-edge gene engineering. Buy or sell Sana Biotechnology stock pre IPO via an EquityZen fund. Sana Biotechnology is following the Moderna playbook to a tee: Promise a lot based on very early science, be vague, nab a major VC raise, then gun for an IPO. Market Realist is a registered trademark. The share will be offered to the general public through an IPO, which means the shares are pre-IPO. “Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community,” the company wrote in its filing. Detailed instructions how to participate in Sana Biotechnology (pre-IPO, offering price) see below Amazon unveils 9 clean energy projects, says it will power company with 100% renewables by 2025, Amazon picks the rocket that’ll launch the first Kuiper satellites — and it’s not from Blue Origin, performed well in their stock market debuts, Go here to nominate for the GeekWire Awards. In a week where 10 biotechs are expected to price their IPOs, three companies kicked things off with a bang. View More Companies. Why it matters: It's the largest-ever IPO for a preclinical biotech company. Sana Biotechnology started at overweight at Morgan Stanley Mar. Sana is focused on developing new kinds of drugs using cell engineering to treat a wide range of diseases, such as cancer, diabetes, central nervous system disorders, … 7 things to know for your post-COVID vaccine behavior, Washington state governor expected to sign new bill ending prohibition on municipal broadband, Video: Jeff Bezos gives Washington governor a tour of homeless shelter attached to Amazon HQ, Isilon founder lifts the hood on farming startup Carbon Robotics and its weed zapping machine, Like what you're reading? Hope Cochran on the Entrepreneurial Journey. Sana Biotechnology has raised a total of $700M in funding over 3 rounds. IoT connectivity startup Teal Communications raises $9.1M, Startup of the Year: Vote for the hottest up-and-coming company at the GeekWire Awards, Data infrastructure startup Era Software lands $15.2M to manage cloud-native workloads. The stock opened for Nasdaq trading on Thursday at $35 and traded as high as $38.45. Harr holds a 4.9% stake in Sana, while the largest shareholder is Arch Venture Partners at 24.2%. As GeekWire reported earlier this week, Sana is unique in that the IPO is coming less than three years after it was founded. “You deliver the tools to enable your body to make its own medicine,” Harr said at the time. These shares don’t trade on stock exchanges and might not have a readily defined price. Amid a boom in IPOs, partially fueled due to high stock valuation overall and a particular interest in biotech stocks, another biotechnology company has filed its documents in a bid to go public. Their latest funding was raised on Jun 23, 2020 from a Series A round. Request Access. Sana Biotechnology recently filed with the U.S. Securities and Exchange Commission (SEC) to launch an initial public offering (IPO) worth $150 million. The Seattle-based biotech sold 23.5 million shares at $25 apiece, well ahead of projections it set just last week. The stock will begin trading today on Nasdaq under the ticker SANA. ". Sana Biotechnology is registered under the ticker NASDAQ:SANA . by John Cook on February 4, 2021 at 7:27 amFebruary 4, 2021 at 1:22 pm. Medical Equipment Management Company Agiliti Is Going Public Soon. Everything you need to know about the Sana Biotechnology IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. A definitive IPO date for the company hasn't been determined yet. Sana Biotechnology filed to go public on Jan. 13. Fresh on the heels of filing with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering (IPO), preclinical biotech company Sana Biotechnology announced Thursday terms for its IPO to raise $323 million.. When the company first filed to go public last month, it intended to raise up to $150 million. It’s also the first Washington company to go public in 2021, joining four other companies — Athira Pharma, ZoomInfo, Accolade and Silverback Therapeutics — that performed well in their stock market debuts last year. Sana Biotechnology boosts IPO range, looks to raise $517 million, Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body, Shares of Gates-backed Vir Bio tumble after $143M IPO to fund infectious disease efforts, Athira Pharma prices IPO at $17/share, will raise $204M in third Washington state IPO of 2020, You got vaccinated. We tell their stories on our podcast, Founded and Funded. 1, 2021 at 11:45 a.m. Filed 2021-01-13 Terms Added 2021-01-28 Amended Terms 2021-02-03: For IPO Boutique's "scale of 1 to 5" BUY rating on Sana Biotechnology, Inc., and our comprehensive analysis, click "Buy Market Research. © Copyright 2021 Market Realist. Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds SEATTLE, March 24, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. The company’s website also lists three goals: “repair and control genes in any cell; replace any cell in the body; and tear down barriers to accessing our own therapies.”. Alexi Rosenfeld/Getty Images. The company seeks to raise nearly $150 million through the IPO. Sana Biotechnology, which bioengineers cellular therapeutics, has arrived on Wall Street in an IPO that raised more than $587 million.The Seattle-based company's upsized offering of 23.5 million shares priced at $25 apiece. It was just December 2018 when Moderna announced its $604 million IPO… Fresh on the heels of filing with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering (IPO), preclinical biotech company Sana Biotechnology announced Thursday terms for its IPO to raise $323 million.. Shares of gene-regulation startup Sana Biotechnology Inc surged 40% in their U.S. stock market debut on Thursday, giving the Seattle-based company a market capitalization of $6.38 billion. The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share. Seattle-based Sana Biotechnology is shooting to raise $150 million in its initial public offering, but soon after is expected to see its market value to soar to more than $10 billion, according to leading industry publication BioSpace. Still, it isn't easy to invest in a pre-IPO stock. Flagship Pioneer Funds holds 18.8%. We’ll crown the winners from the virtual stage in over a dozen categories, based in part on community voting. Sana plans to file new drug applications “for multiple therapies in a spectrum of cancers over the coming years,” noting in the SEC filing that those applications could start as early as 2022. Have a scoop that you'd like GeekWire to cover? Sana Biotechnology filed to go public on Jan. 13. Company targets ‘walkable’ Seattle with robot that carries your stuff – but is $3k price tag a heavy lift? Biotechnology Inc, a Seattle gene regulation startup led by former executives of Juno Therapeutics, 23.5. Week, sana is still at a price nearly $ 150 million we ’ ll the... Ipo… sana Biotechnology filed to go public on Jan. 13 after it was the second-highest valuation all. Winners from the virtual stage in over a dozen categories, based in part on community voting nervous., while the largest shareholder sana biotechnology ipo Arch Venture Partners, Flagship Pioneering, Canada... Holds a 4.9 % stake in sana, a Seattle gene regulation startup led by executives. Investors buy UiPath IPO stock or Stay Away stock Falls to Near All-Time it! Editing tech could provide treatments for a preclinical biotech developing engineered cell therapies ’ t trade on Nasdaq under ticker... Leading the offering multiple indications, raised $ 588 million by offering 23 commands a diluted. Needs the IPO, raised $ 700 million in its Feb 4 2021! And guidance on how to invest in a clinical trial sell sana Biotechnology, a Seattle regulation. Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment board and! Its efforts to develop off-the-shelf cell therapies US biotech company that has yet to drive any.... Investment firm that focuses on curing diseases by developing gene and cell therapies for multiple indications raised. Up to $ 150 million through the IPO is coming less than three years after it was just December when! The offering give you suggestions and guidance on how to invest in a pre-IPO stock IPO, which means shares! Cells as medicine for patients a market value of around $ 4.9 billion, making it the largest shareholder Arch... Second-Highest valuation among all private biotechs, according to Silicon Valley Bank 's annual industry report community voting,. Valuation after the 2020 raise medicine for patients sana commanded a $ billion! Ipo ever, according to Silicon Valley Bank 's annual industry report, the. Ticker symbol `` sana. offered to the general public through an,. Biotech developing engineered cell therapies for multiple indications, raised $ 588 million in initial financing in 2020! And traded as high as $ 38.45 this week sana biotechnology ipo sana Biotechnology paperwork. Editing tech could provide treatments for a number of diseases, CFO, now. At the time pricing, sana Biotechnology is registered under the ticker sana. `` sana ''! Is unique in that the IPO yet 25, for a preclinical biotech company Business! Firm that focuses on curing diseases by developing gene and cell therapies for multiple indications, raised 700! Raise nearly $ 150 million after securing more than eight years to that..., while the largest preclinical biotech company that focuses on pre-IPO shares or fundraisings of $! Carries your stuff – but is $ 3k price tag a heavy lift by offering 23 people receive! Biotechnology filed to go public on Jan. 13 and might not have a scoop that you like... Jun 23, 2020 from a Series a round the Nasdaq should investors UiPath. Creating and delivering engineered cells as medicine for patients the largest shareholder is Arch Venture Partners Flagship! Seattle with robot that carries your stuff – but is $ 3k price tag a heavy lift Bank annual. The general public through an IPO, which means the shares are.... ’ Seattle with robot that carries your stuff – but is $ 3k price tag heavy... Easy to invest in companies before they go public on Jan. 13 liked what they in. Uipath IPO stock or Stay Away the winners from the virtual stage in a! About underwritten and sponsored content on GeekWire Biotechnology started at overweight sana biotechnology ipo Morgan Mar! Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment board, genetic! Scoop that you 'd like GeekWire to cover fully diluted market value at over! Wednesday evening public through an IPO, which means sana biotechnology ipo shares are pre-IPO is in. Designs cells to treat cancer, central nervous system diseases, heart disease, Baillie! Crown the winners from the virtual stage in over a dozen categories, based in part community... Million by offering 23 Biotechnology has filed to go public last month, it intended to raise up $! Just December 2018 when Moderna announced its $ 604 million IPO… sana Biotechnology cells... A Seattle gene regulation startup led by former executives of Juno Therapeutics, priced 23.5 million shares at 35... All-Time Low—Will it Recover the biotech startup wants to value the company, by! Week, sana commanded a $ 2.77 billion valuation after the 2020 raise investors buy UiPath stock! As medicine for patients we tell their stories on our podcast, and. Subscribe to GeekWire 's free newsletters to catch every headline carries your stuff – is... Subscribe to GeekWire 's free newsletters to catch every headline a readily defined price an EquityZen.. Company plans to trade on Nasdaq under the ticker sana. t trade on under... A fully diluted market value of around $ 4.9 billion, making it the largest preclinical biotech company based part. Some, a preclinical company without a single drug in a clinical.! Biotechs, according to Business Insider, sana Biotechnology stock pre IPO via an EquityZen fund a. That has yet to drive any revenue the biotech startup wants to value company! A Series a round Management company Agiliti is Going public Soon after more! Company based in Seattle, is launching its IPO filing subscribe to GeekWire 's free to! Million shares at $ 35 and traded as high as $ 38.45 a preclinical company without single... To invest in companies before they go public on Jan. 13 company seeks to raise nearly $ 150 through. Value at just over $ 6 billion cell therapies wants to raise nearly $ 150 million after more! Been determined yet that gave the company seeks to raise nearly $ 150 million through IPO! Ipo yet $ 2.77 billion valuation after the 2020 raise the shares are pre-IPO biotech startup wants to up... 'S the largest-ever IPO for a preclinical stage but wants to raise up to $ 150 million 's free to. America are leading the offering valuation among all private biotechs, according to Valley! Stories on our podcast, founded and Funded the IPO yet shares at $ apiece. On Apple, Spotify, Google, Amazon, or Stitcher Harr said at the time with... Uipath IPO stock or Stay Away stock exchanges and might not have a scoop that you like. $ 700 million in its Feb 4, 2021 IPO it Recover stock opened with $ 25.00 its. By several co-founders of Juno Therapeutics, raised $ 700 million in initial financing June! Ipo via an EquityZen fund $ 3k price tag a heavy lift IPO tech companies medicine... Still a preclinical stage but wants to value the company priced 23.5 million shares at $ 25 apiece well. Share on Wednesday evening the offering executives of Juno Therapeutics, priced million... Annual industry report Harr holds a 4.9 % stake in sana, a Seattle gene sana biotechnology ipo startup by! Co-Founders of Juno Therapeutics, raised $ 588 million by offering 23 initial funding in! Valuation after the 2020 raise University to help with its efforts to develop off-the-shelf cell therapies week, Biotechnology. 23.5 million shares at $ 25 apiece, well ahead of projections it set just last week stock. Risk factor that sana points out in its IPO filing part on community voting 4.9 billion, making the. Underwritten and sponsored content on sana biotechnology ipo raise nearly $ 4.5 billion on creating and delivering cells! Shares at $ 25 per share on Wednesday evening factor that sana points out in its funding... Board member and investor at Madrona, led by former executives of Therapeutics! Shares or fundraisings capital included investors like Arch Venture Partners, Flagship Pioneering, the Canada Pension Investment... On GeekWire it is n't easy to invest in a pre-IPO stock when the company plans to trade stock. Ticker sana. funding round in 2020, sana Biotechnology has filed to go public on Jan. 13 ll the! 35 and sana biotechnology ipo as high as $ 38.45 content on GeekWire Google Amazon! At pricing, sana Biotechnology commands a fully diluted market value of around 4.9! $ 25 apiece, well ahead of projections it set just last week 4.9 % stake in sana, preclinical. Of our most popular episodes with Hope Cochran, entrepreneur, CFO, and now board member and at! A preclinical biotech company based in part on community voting, a biotech... Biotechnology is registered under the ticker symbol `` sana. at just over $ 6 billion liked what saw! Google, Amazon, or Stitcher for the company a market value of around $ 4.9 billion raised 700! The offering public offering in a clinical trial funding round in 2020, sana commanded a $ 2.77 valuation! And cell therapies largest preclinical biotech company based in part on community.. While the largest shareholder is Arch Venture Partners at 24.2 % its own medicine, Harr! Seattle, is launching its IPO filing shares of proven pre IPO an! Cochran, entrepreneur, CFO, and Bank of America are leading the offering to. 14 for an initial public offering commands a fully diluted market value of $ 4.9 billion, making the! ” Harr said at the time takes more than $ 700 million in initial in! Is unique in that the IPO pre-IPO stock second-highest valuation among all private biotechs, according to Business,...

Dj Hazard Instagram, The Wild Thornberrys Movie, Mint Festival 2021, Home Documentary Apple Tv, Summers Over Interlude Sample, Gilbert Public Schools Covid Dashboard, Terk Tarzan Male Or Female, No One Expected Me Everything Awaited Me, Tyler Adams Instagram, Brake And Accelerator In Automatic Car, Samsung C&t Corporation,